Skip to main content
Premium Trial:

Request an Annual Quote

Cue Health Nabs CE Mark for Molecular Point-of-Care COVID-19 Test

NEW YORK ─ Cue Health said on Tuesday that it has received the CE mark for its molecular point-of-care COVID-19 test, clearing it for sale in the European Union and other regions that accept the designation.

The nucleic acid amplification test ─ compact enough to fit in the palm of a hand ─ consists of the single-use Cue Test Cartridge and the Cue Sample Wand, a lower nasal swab for sample collection. It runs on the Cue Health Monitoring System and displays test results on a connected mobile device in about 20 minutes via an app. A reusable, battery-operated reader and the cartridge communicate results directly to the health app, the firm said.

San Diego-based Cue added that US-based K-12 schools, essential businesses, hospitals, physicians' offices, dental clinics, nursing homes, and other congregate-care facilities are already using its COVID-19 test. It is also being used in several states under a program led by the US Department of Defense and the US Department of Health and Human Services.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.